The contrasting roles of Dysferlin during tumor progression in renal cell carcinoma.
CONCLUSION: DYSF mRNA and protein expression are opposingly involved in tumor progression of ccRCC. DYSF could be used as a prognostic biomarker to predict survival of patients with ccRCC.
PMID: 32430251 [PubMed - as supplied by publisher]
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Cox A, Zhao C, Tolkach Y, Nettersheim D, Schmidt D, Kristiansen G, Hauser S, Müller SC, Ritter M, Ellinger J Tags: Urol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Cardiology | Gastroschisis Repair | Heart | Kidney Cancer | Renal Cell Carcinoma | Statistics | Study | Urology & Nephrology